Skip to content
Home/Companies/Healthcare/Timberlyne Therapeutics

Timberlyne Therapeutics

Healthcare·US·Active·1yr hold
Entry
2025
Hold
1yr
Status
Active

Who owns Timberlyne Therapeutics?

Timberlyne Therapeutics is currently owned by Abingworth through Abingworth Bioventures 8 (2021 vintage), since 2025.

Hand-verified · updated 2026-06-10

Abingworth
Investor
Abingworth
Abingworth Bioventures 8 · 2021 · Life Sciences VC

Key facts

HQUS
SectorHealthcare
StatusActive

More from Abingworth Bioventures 8

Other portfolio companies in the same fund.

Cytospire Therapeutics
Cytospire Therapeutics
Active
BiotechUK· 2026
AdvanCell
Active
BiotechAustralia· 2025
Antares Therapeutics
Active
BiotechUS· 2025
Solve Therapeutics
Active
BiotechUS· 2025
Myricx Bio
Myricx Bio
Exited 2026
BiotechUK· 2024
to
Ascend Gene & Cell Therapies
Ascend Gene & Cell Therapies
Active
BiotechUK· 2023

More PE-backed in Healthcare

Comparable healthcare deals from other GPs.

3i – Implant Innovations Inc.
Active
Advent InternationalUS
A Place for Mom
A Place for Mom
Active
Silver LakeUS
Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
Abbisko Healthcare
Active
The Carlyle GroupChina
Abode Healthcare
Active
Summit PartnersUS
AccentCare
AccentCare
Active
Advent InternationalUS
Track Timberlyne Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Timberlyne Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue